



## The Angiosome Concept: How to Connect the Right Arterial Segments?

Peter A. Schneider, MD

Division of Vascular Therapy
Hawaii Permanente Medical Group
Honolulu, Hawaii



#### **Disclosure**

Peter A. Schneider

I have the following disclosures:


- X Scientific Advisory Board: AbbottVascular, Medtronic
- X Royalties: Cook
- X Educational programs: Medtronic, Gore, Cook, Terumo
- X Steering Committee for VIVA
- X Enroll in clinical studies with sponsors: Cordis, Abbott, Gore

## Old Teachings


- "Must establish in-line flow to the foot"
  - Typically with bypass, we are looking for the best quality target blood vessel to work with.

#### Limb Amputation or Clinical Failure Despite a Patent Bypass

Study	<b>CLI Patients</b>	Results
Goodney at al Ann Vasc Surg 2010;24:59	2306 bypass	8% amputation at one year, 17% of these had a patent bypass
Simons et al. J Vasc Surg 2010;51:1419	1012 bypass	10% of those with a patent graft had no clinical improvement
Taylor et al J Vasc Surg 2009;50:534	361 bypass 316 PTA	Survival, limb salvage, and ambulation for one year: 37% for PTA and 44% for bypass



A fully intact pedal arch is rare in diabetics.



## Angiosomes of the Foot and Ankle




### Targeted tibial revascularization

- Opportunity to match the treatment to the clinical syndrome (Analogous to coronary bed)
- Why not achieve best possible perfusion to the tissue in need?



Opportunity for targeted therapy



# Strategy for BTK Angioplasty Angiosomal Perfusion Matters

## Method of Revasc

Appropriate Angiosome Treated Boundary Angiosome Treated

PTA

Alexandrescu et al. J Endovasc Ther 2008;15:580 83% healed

59% healed


**Bypass** 

Neville et al. Ann Vasc Surg 2009;23:367 91% healed

62% healed

## Angiosome Concept

Comparison of BTK Angioplasty in Diabetics With and Without Use of the Angiosome Concept



Alexandrescu et al. J Endovasc Ther 2011;18:376

## Angiosome Concept

Composite of renal failure and angiosomal perfusion






Figure 3. Results of Cox multiple regression analysis: predicted primary clinical patency in the treated limb for "good" and "poor" groups. "Good" = serum creatinine level  $\leq 130~\mu \text{mol/L}$  and angiographic improvement of arterial filling at the site of the most severe ischemia. "Poor" = serum creatinine level  $> 130~\mu \text{mol/L}$  and no angiographic improvement.

Exploit the Advantages of Endovascular Therapy





# When is Angiosome concept less important?

- Non-diabetics
- Rest pain (Rutherford 4), no tissue loss
- Lesion above the ankle
- Superficial ulceration (<10mm in diameter), esp. if toe pressure <20mmHg after PTA</li>
- Fully intact pedal arch





Angiosomal Variability




Medial plantar artery

Attinger. Plast Reconstr Surg 2006;117:261

# Angiosome Concept Need More Understanding

- Angiosomal variability.
- Differences in collateralization
  - Example: variable affect peroneal artery revasc
- When to revasc a boundary angiosome.
- Match angiosomal revascularization to tissue perfusion

# Angiosome Concept How Can It Guide Therapy?



Angiosome Concept
How Can It Guide Therapy?





## Angiosome Concept Conclusions

- Helps to explain some of the variability in results of revascularization for CLI.
  - Especially in diabetics
- Healing is more likely after direct revasc of the correct angiosome.
- An opportunity for targeted therapy.
- May help determine best strategy in some subgroups of patients.